Gamble Program for Clinical Studies

  • Gamble Program for Clinical Studies

    A program within the Infectious Diseases Division at Cincinnati Children’s, the Gamble Program for Clinical Studies is responsible for the management of the clinical trials program. The emphasis of the clinical trials is on vaccines and antivirals. The studies include all ages, from infants to the elderly.

    The Gamble Program for Clinical Studies is focused on the diagnosis, prevention and treatment of diseases caused by viruses such as:

    • Influenza
    • Rotavirus
    • Cytomegalovirus
    • Hepatitis
    • Herpes simplex
    • Other causes of diarrhea and respiratory infections

    In 1994 and again in 2001 and 2007, the Gamble Program was designated as one of seven Vaccine and Treatment Evaluation Units (VTEUs) of the National Institute of Allergy and Infectious Diseases of the NIH. These seven-year contracts are dedicated to finding improved vaccines and better treatments for infectious diseases. The Gamble Program’s scope of activities include:

    • Development and evaluation of diagnostic assays, vaccines and antiviral drugs
    • Surveillance of viral and bacterial diseases
    • Development of newer, improved vaccine delivery systems and adjuvants
    • Education about viral diseases, vaccine use and treatment status to lay, paramedical and medical communities.
 
  • Spotlight:

    “Children’s Awarded $23.7 Million NIH Contract”

    Cincinnati Children’s has received a seven-year, $23.7 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), as one of eight Vaccine and Treatment Evaluation Units (VTEUs) in the United States.

    The funding is among the largest contracts or grants that Cincinnati Children’s has received.